	US 12,076,371 B2
	Activatable cytokine polypeptides and methods of use thereof
William Winston, West Newton, MA (US); Daniel Hicklin, Boston, MA (US); Jose Andres Salemeron-Garcia, Acton, MA (US); Heather Brodkin, West Newton, MA (US); and Cynthia Seidel-Dugan, Belmont, MA (US)
Assigned to Werewolf Therapeutics, Inc., Cambridge, MA (US)
Filed by Werewolf Therapeutics, Inc., Cambridge, MA (US)
Filed on Feb. 9, 2023, as Appl. No. 18/166,700.
Application 18/166,700 is a continuation of application No. 17/934,811, filed on Sep. 23, 2022.
Application 17/934,811 is a continuation of application No. 17/741,275, filed on May 10, 2022.
Application 17/741,275 is a continuation of application No. PCT/US2020/060624, filed on Nov. 14, 2020.
Claims priority of provisional application 62/935,605, filed on Nov. 14, 2019.
Prior Publication US 2024/0033326 A1, Feb. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/64 (2017.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01)

CPC A61K 38/2013 (2013.01) [A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 38/208 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); A61K 47/6425 (2017.08); A61K 47/65 (2017.08); A61K 47/6813 (2017.08); A61K 47/6845 (2017.08); A61P 31/12 (2018.01); A61P 35/00 (2018.01); C12N 15/63 (2013.01)]

29 Claims

1. A fusion polypeptide having the formula of: [D]-[L1]-[A]-[L2′]-[H], wherein,

[A] is an interferon alpha (IFNa) polypeptide, a mutein, or an active fragment thereof,

[D] is a blocking moiety,

[H] is a half-life extension moiety,

[L1] is a protease-cleavable polypeptide linker comprising the amino acid sequence of SEQ ID NO: 609, 612, or 615, and

[L2′] is a protease-cleavable polypeptide linker comprising the amino acid sequence of SEQ ID NO: 609, 612, or 615,

wherein the blocking moiety and the half-life extension moiety each independently comprise human serum albumin (HSA) or an antibody or antibody fragment that binds the HSA.